gentamycin and clindamycin

ApprovedSmall molecule

SShahid Beheshti University of Medical Sciences

gentamycin and clindamycin is one of 5 small molecule programs targeting Endophthalmitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EndophthalmitisActive, not recruiting

EndophthalmitisApproved

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Endophthalmitis

#DrugCompanyPhaseTrials

Avelox

Bayer

Approved

5 2

Cipro

Bayer

Phase 2

1 3

gentamycin and clindamycin

SShahid Beheshti University of Medical Sciences

Approved

1 4

Ceftin

PPhiladelphia Eye Associates

Preclinical

1 5

Levaquin

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Endophthalmitis1 trial

Prophylaxis of Acute Post-Traumatic Bacterial Endophthalmitis

Completed·SShahid Beheshti University of Medical Sciences·Phase 4·NCT00398658

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for gentamycin and clindamycin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gentamycin and clindamycin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gentamycin and clindamycin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shahid Beheshti University of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SShahid Beheshti University of Medical Sciences

gentamycin and clindamycin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Endophthalmitis1 trial

References

Drug Info

Quick Facts

Related News